SCHEMBL5887567

SCHEMBL5887567

CS(=O)(=O)C1=CC[CH]C(c2ccc3ccccc3c2)=C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
PTGS2 P35354 4/20 0.38
GSTP1 P09211 1/20 0.37
PTGS1 P23219 1/20 0.36
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
SLC6A3 Q01959 4/20 0.33
LMNA P02545 1/20 0.33
ALOX5 P09917 1/20 0.33
SLC6A2 P23975 3/20 0.32
SLC6A4 P31645 1/20 0.32
KCNH2 Q12809 1/20 0.32
CA12 O43570 1/20 0.32
IKBKB O14920 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887472 0.79 PGR (0.41) CA1CA2CA9PTGS2GSTP1
SCHEMBL27459545 0.78 GSTP1 (0.47) CA1CA2CA9GSTP1ESR1
SCHEMBL4004153 0.74 CYP2A6 (0.38) CA1CA2CA9GSTP1ESR1
SCHEMBL4007380 0.74 PTGS2 (0.36) CA1CA2CA9PTGS2PTGS1
SCHEMBL4005351 0.74 HTR1D (0.36) CA1CA2CA9GSTP1ESR1
SCHEMBL4808925 0.74 GSTP1 (0.35) CA1CA2CA9GSTP1ESR1
SCHEMBL5887031 0.71 CDC25A (0.44) GSTP1L3MBTL1ESR1ESR2SLC6A3
SCHEMBL4009020 0.71 GSTP1 (0.35) GSTP1ESR1ESR2ALOX5CA12
SCHEMBL6897810 0.68 CYP1A2 (0.41) CA1CA2CA9GSTP1ESR1
SCHEMBL30712199 0.66 CA1 (0.68) CA1CA2CA9PTGS2GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 CA1 924/4885CA2 1774/4885CA9 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.